Cost Consequences Associated With Biologic Therapy Switching in Publicly Insured Psoriasis Individuals in the United States. Sun QW, Damsky WE, Cohen JM. Int J Dermatol 2026 Feb 6. doi: 10.1111/ijd.70325.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun QW, Damsky WE, Cohen JM. Cost Consequences Associated With Biologic Therapy Switching in Publicly Insured Psoriasis Individuals in the United States. Int J Dermatol 2026 Feb 6. doi: 10.1111/ijd.70325.
PMID: 41649376